Subject of the day
VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
FY 2013–2025 · 13 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $517.14M | +55.2% | |
| Gross profit | $229.68M | -23.0% | |
| Operating income | $16.14M | +0.0% | |
| Net income | $66.35M | +174.9% | |
| Cash from ops | $44.22M | +80.4% |
$42.60
▼ -2.08 (-4.7%)
| 52w hi | $60.49 |
|---|---|
| 52w lo | $28.61 |
| Vol | 1.43M |
| As of | Aug 13 |
Our score +0.10
| Short | -0.13 |
|---|---|
| Medium | +0.22 |
| Long | +0.32 |
computed 2026-08-13
Veracyte, Inc.
Healthcare · Diagnostics & Research
| Market cap | $3.42B |
|---|---|
| Enterprise value | $3.15B |
| Trailing P/E | 30.43x |
| Forward P/E | 21.87x |
| EV / EBITDA | 27.72x |
| P / S (ttm) | 6.09x |
| Profit margin | 20.4% |
| Return on equity | 8.8% |
| Revenue growth | +15.5% |
| Earnings growth | — |
| Debt / equity | 2.89 |
| Beta vs SPX | 1.36 |
|---|---|
| Corr SPX | 0.37 |
| Annual vol | 60.2% |
| Annual ret | +52.8% |
| Sharpe | 0.88 |
| Max DD | -50.1% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.25 | |
| Sector | +0.12 | |
| Technical | +0.00 | |
| Earnings | +0.00 | |
| Sentiment | -0.03 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $45.23 | $45.23 | $42.51 | $42.60 | 1.43M |
| Aug 12 | $46.54 | $46.76 | $44.28 | $44.68 | 874.00K |
| Aug 11 | $46.07 | $46.67 | $45.72 | — | 542.32K |
| Aug 10 | $46.87 | $47.75 | $46.12 | $46.27 | 761.80K |
| Aug 7 | $47.00 | $47.80 | $46.21 | $47.22 | 821.30K |